If approved, Molbreevi could be the first FDA-approved treatment for patients with autoimmune pulmonary alveolar proteinosis, ...
Tryngolza is once-monthly, subcutaneous RNA-targeted therapy and is expected to be available by the end of the year with a ...
A new study shows that nearly 90% of patients with moderate-to-severe atopic dermatitis (AD) reported their condition ...
The new, now-defeated bill eliminated the PBM reform measures included in a larger spending bill that the president-elect and ...
The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to ...
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
Women are more than twice as likely to develop post-traumatic stress disorder than men, and a new study demonstrates for the ...
The boxed warning follows a safety warning the FDA issued in September about the risk of liver injury from the use of Veozah ...
A new bill in Congress would require pass-through prices in both Medicare, and Medicaid and require transparency of PBM ...
A pooled analysis of two prior trials suggests patients with a variety of cardiac index scores saw improvement when Winrevair ...
Anna Podolanczuk, M.D., M.S., discusses how the mortality rates for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are impacted by comorbidities, including ...
In past trials, ketamine intravenous treatment has shown promise, with 64% of depression patients in trials experiencing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback